CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma

CYFRA 21-1 is a prognostic marker for non–small cell lung cancer. The serum CYFRA 21-1 level is also known as an adjunct for the diagnosis of lung squamous cell carcinoma. This study aimed to examine whether CYFRA 21-1 has predictive implications for nivolumab therapy in patients with advanced lung...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology 2018-02, Vol.40 (2), p.1010428318760420-1010428318760420
Main Authors: Shirasu, Hiromichi, Ono, Akira, Omae, Katsuhiro, Nakashima, Kazuhisa, Omori, Shota, Wakuda, Kazushige, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Endo, Masahiro, Nakajima, Takashi, Takahashi, Toshiaki
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma - drug therapy
Adenocarcinoma - metabolism
Adenocarcinoma of Lung
Adult
Aged
Antibodies, Monoclonal - therapeutic use
Antigens
Antigens, Neoplasm - metabolism
Authorship
Biomarkers, Tumor - metabolism
Cancer therapies
Carcinoembryonic antigen
Carcinoembryonic Antigen - metabolism
Chemotherapy
Clinical medicine
Disease-Free Survival
Enzymes
Epidermal growth factor
ErbB Receptors - metabolism
Ethics
Female
Follow-Up Studies
Histology
Humans
Immunoassay
Immunotherapy
Keratin-19 - metabolism
Lung cancer
Lung carcinoma
Lung Neoplasms - drug therapy
Lung Neoplasms - metabolism
Male
Middle Aged
Monoclonal antibodies
Multivariate analysis
Mutation
Nivolumab
Non-small cell lung carcinoma
Patients
Pharmaceuticals
Research funding
Retrospective Studies
Smoking
Squamous cell carcinoma
Statistical analysis
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3880-a15e86f7045fe9d4fc0faf7b05903cc774b8587f5d97213aaba33494f483bcb23
cites cdi_FETCH-LOGICAL-c3880-a15e86f7045fe9d4fc0faf7b05903cc774b8587f5d97213aaba33494f483bcb23
container_end_page 1010428318760420
container_issue 2
container_start_page 1010428318760420
container_title Tumor biology
container_volume 40
creator Shirasu, Hiromichi
Ono, Akira
Omae, Katsuhiro
Nakashima, Kazuhisa
Omori, Shota
Wakuda, Kazushige
Kenmotsu, Hirotsugu
Naito, Tateaki
Murakami, Haruyasu
Endo, Masahiro
Nakajima, Takashi
Takahashi, Toshiaki
description CYFRA 21-1 is a prognostic marker for non–small cell lung cancer. The serum CYFRA 21-1 level is also known as an adjunct for the diagnosis of lung squamous cell carcinoma. This study aimed to examine whether CYFRA 21-1 has predictive implications for nivolumab therapy in patients with advanced lung adenocarcinoma. Of the 79 patients who were treated with nivolumab therapy at the Shizuoka Cancer Center between December 2015 and September 2016, we retrospectively reviewed the data of 50 patients. The patient characteristics were as follows: age
doi_str_mv 10.1177/1010428318760420
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_1a88b2cad8c4438abaed8a8e42f13033</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1010428318760420</sage_id><doaj_id>oai_doaj_org_article_1a88b2cad8c4438abaed8a8e42f13033</doaj_id><sourcerecordid>2007121717</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3880-a15e86f7045fe9d4fc0faf7b05903cc774b8587f5d97213aaba33494f483bcb23</originalsourceid><addsrcrecordid>eNp1kUFrFTEQgIMotj69e5KAl15WZ5LsS_ZYHlYLBUHag3hYZrPJax67m2eyW-m_b9pXKxQ8ZZL55psMw9h7hE-IWn9GQFDCSDR6XQJ4wY5RCVmBNPCyxCVd3eeP2JucdwBYN836NTsSjVpLbOCY_dr8PPtxygVWyPfJ9cHOmc_XjjvvgyV7y6PnU7iJwzJSx8PE9zQHNxXqT5ivOfU3NFnX82GZtuXmpmgp2TDFkd6yV56G7N49nit2dfblcvOtuvj-9XxzelFZaQxUhLUza69B1d41vfIWPHndQd2AtFZr1ZnaaF_3jRYoiTqSUjXKKyM72wm5YucHbx9p1-5TGCndtpFC-_AQ07alNAc7uBbJmE5Y6o1VSpqicr0h45TwKEHK4jo5uPYp_l5cntsxZOuGgSYXl9wKAI0CNeqCfnyG7uKSpjJpoVBq-TDAisGBsinmnJx_-iBCe7_E9vkSS8mHR_HSja5_Kvi7tQJUByDT1v3r-l_hHd70oUE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2013730590</pqid></control><display><type>article</type><title>CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma</title><source>Publicly Available Content Database</source><creator>Shirasu, Hiromichi ; Ono, Akira ; Omae, Katsuhiro ; Nakashima, Kazuhisa ; Omori, Shota ; Wakuda, Kazushige ; Kenmotsu, Hirotsugu ; Naito, Tateaki ; Murakami, Haruyasu ; Endo, Masahiro ; Nakajima, Takashi ; Takahashi, Toshiaki</creator><creatorcontrib>Shirasu, Hiromichi ; Ono, Akira ; Omae, Katsuhiro ; Nakashima, Kazuhisa ; Omori, Shota ; Wakuda, Kazushige ; Kenmotsu, Hirotsugu ; Naito, Tateaki ; Murakami, Haruyasu ; Endo, Masahiro ; Nakajima, Takashi ; Takahashi, Toshiaki</creatorcontrib><description>CYFRA 21-1 is a prognostic marker for non–small cell lung cancer. The serum CYFRA 21-1 level is also known as an adjunct for the diagnosis of lung squamous cell carcinoma. This study aimed to examine whether CYFRA 21-1 has predictive implications for nivolumab therapy in patients with advanced lung adenocarcinoma. Of the 79 patients who were treated with nivolumab therapy at the Shizuoka Cancer Center between December 2015 and September 2016, we retrospectively reviewed the data of 50 patients. The patient characteristics were as follows: age &lt;70/≥70 years: 43 (86%)/7; male/female: 31 (62.0%)/19; Eastern Cooperative Oncology Group performance status 0–1/2: 43 (86%)/7; smoking status: no/yes: 18 (36%)/32; epidermal growth factor receptor mutation status negative/positive: 36 (72%)/14; CYFRA 21-1 ≥2.2/&lt;2.2 ng/mL: 28 (56%)/22; carcinoembryonic antigen ≥5/&lt;5 ng/mL: 29 (58%)/21; and number of prior regimens 2–3/≥4: 16 (32%)/34. With a median follow-up of 263.5 (range, 64–352) days, the median progression-free survival was 70 days. The clinical variables investigated using univariate analysis were as follows: age (p = 0.423), carcinoembryonic antigen (p = 0.888), epidermal growth factor receptor mutation status (p = 0.105), performance status (p = 0.968), sex (p = 0.210), number of prior regimens (p = 0.146), CYFRA 21-1 (p = 0.026), and smoking status (p = 0.041). A multivariate analysis identified a serum CYFRA 21-1 level ≥2.2 ng/mL as an independent predictor of a favorable outcome (hazard ratio, 0.44; 95% confidence interval, 0.23–0.85; p = 0.015; median progression-free survival, 155 vs 51.5 days). In conclusion, CYFRA 21-1 might be an independent predictor of outcome for patients with advanced lung adenocarcinoma treated with nivolumab.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1177/1010428318760420</identifier><identifier>PMID: 29463190</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adenocarcinoma ; Adenocarcinoma - drug therapy ; Adenocarcinoma - metabolism ; Adenocarcinoma of Lung ; Adult ; Aged ; Antibodies, Monoclonal - therapeutic use ; Antigens ; Antigens, Neoplasm - metabolism ; Authorship ; Biomarkers, Tumor - metabolism ; Cancer therapies ; Carcinoembryonic antigen ; Carcinoembryonic Antigen - metabolism ; Chemotherapy ; Clinical medicine ; Disease-Free Survival ; Enzymes ; Epidermal growth factor ; ErbB Receptors - metabolism ; Ethics ; Female ; Follow-Up Studies ; Histology ; Humans ; Immunoassay ; Immunotherapy ; Keratin-19 - metabolism ; Lung cancer ; Lung carcinoma ; Lung Neoplasms - drug therapy ; Lung Neoplasms - metabolism ; Male ; Middle Aged ; Monoclonal antibodies ; Multivariate analysis ; Mutation ; Nivolumab ; Non-small cell lung carcinoma ; Patients ; Pharmaceuticals ; Research funding ; Retrospective Studies ; Smoking ; Squamous cell carcinoma ; Statistical analysis ; Targeted cancer therapy ; Tumors</subject><ispartof>Tumor biology, 2018-02, Vol.40 (2), p.1010428318760420-1010428318760420</ispartof><rights>The Author(s) 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3880-a15e86f7045fe9d4fc0faf7b05903cc774b8587f5d97213aaba33494f483bcb23</citedby><cites>FETCH-LOGICAL-c3880-a15e86f7045fe9d4fc0faf7b05903cc774b8587f5d97213aaba33494f483bcb23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2013730590/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2013730590?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,44590,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29463190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shirasu, Hiromichi</creatorcontrib><creatorcontrib>Ono, Akira</creatorcontrib><creatorcontrib>Omae, Katsuhiro</creatorcontrib><creatorcontrib>Nakashima, Kazuhisa</creatorcontrib><creatorcontrib>Omori, Shota</creatorcontrib><creatorcontrib>Wakuda, Kazushige</creatorcontrib><creatorcontrib>Kenmotsu, Hirotsugu</creatorcontrib><creatorcontrib>Naito, Tateaki</creatorcontrib><creatorcontrib>Murakami, Haruyasu</creatorcontrib><creatorcontrib>Endo, Masahiro</creatorcontrib><creatorcontrib>Nakajima, Takashi</creatorcontrib><creatorcontrib>Takahashi, Toshiaki</creatorcontrib><title>CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma</title><title>Tumor biology</title><addtitle>Tumour Biol</addtitle><description>CYFRA 21-1 is a prognostic marker for non–small cell lung cancer. The serum CYFRA 21-1 level is also known as an adjunct for the diagnosis of lung squamous cell carcinoma. This study aimed to examine whether CYFRA 21-1 has predictive implications for nivolumab therapy in patients with advanced lung adenocarcinoma. Of the 79 patients who were treated with nivolumab therapy at the Shizuoka Cancer Center between December 2015 and September 2016, we retrospectively reviewed the data of 50 patients. The patient characteristics were as follows: age &lt;70/≥70 years: 43 (86%)/7; male/female: 31 (62.0%)/19; Eastern Cooperative Oncology Group performance status 0–1/2: 43 (86%)/7; smoking status: no/yes: 18 (36%)/32; epidermal growth factor receptor mutation status negative/positive: 36 (72%)/14; CYFRA 21-1 ≥2.2/&lt;2.2 ng/mL: 28 (56%)/22; carcinoembryonic antigen ≥5/&lt;5 ng/mL: 29 (58%)/21; and number of prior regimens 2–3/≥4: 16 (32%)/34. With a median follow-up of 263.5 (range, 64–352) days, the median progression-free survival was 70 days. The clinical variables investigated using univariate analysis were as follows: age (p = 0.423), carcinoembryonic antigen (p = 0.888), epidermal growth factor receptor mutation status (p = 0.105), performance status (p = 0.968), sex (p = 0.210), number of prior regimens (p = 0.146), CYFRA 21-1 (p = 0.026), and smoking status (p = 0.041). A multivariate analysis identified a serum CYFRA 21-1 level ≥2.2 ng/mL as an independent predictor of a favorable outcome (hazard ratio, 0.44; 95% confidence interval, 0.23–0.85; p = 0.015; median progression-free survival, 155 vs 51.5 days). In conclusion, CYFRA 21-1 might be an independent predictor of outcome for patients with advanced lung adenocarcinoma treated with nivolumab.</description><subject>Adenocarcinoma</subject><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma of Lung</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antigens</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Authorship</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer therapies</subject><subject>Carcinoembryonic antigen</subject><subject>Carcinoembryonic Antigen - metabolism</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Disease-Free Survival</subject><subject>Enzymes</subject><subject>Epidermal growth factor</subject><subject>ErbB Receptors - metabolism</subject><subject>Ethics</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Histology</subject><subject>Humans</subject><subject>Immunoassay</subject><subject>Immunotherapy</subject><subject>Keratin-19 - metabolism</subject><subject>Lung cancer</subject><subject>Lung carcinoma</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multivariate analysis</subject><subject>Mutation</subject><subject>Nivolumab</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Pharmaceuticals</subject><subject>Research funding</subject><subject>Retrospective Studies</subject><subject>Smoking</subject><subject>Squamous cell carcinoma</subject><subject>Statistical analysis</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kUFrFTEQgIMotj69e5KAl15WZ5LsS_ZYHlYLBUHag3hYZrPJax67m2eyW-m_b9pXKxQ8ZZL55psMw9h7hE-IWn9GQFDCSDR6XQJ4wY5RCVmBNPCyxCVd3eeP2JucdwBYN836NTsSjVpLbOCY_dr8PPtxygVWyPfJ9cHOmc_XjjvvgyV7y6PnU7iJwzJSx8PE9zQHNxXqT5ivOfU3NFnX82GZtuXmpmgp2TDFkd6yV56G7N49nit2dfblcvOtuvj-9XxzelFZaQxUhLUza69B1d41vfIWPHndQd2AtFZr1ZnaaF_3jRYoiTqSUjXKKyM72wm5YucHbx9p1-5TGCndtpFC-_AQ07alNAc7uBbJmE5Y6o1VSpqicr0h45TwKEHK4jo5uPYp_l5cntsxZOuGgSYXl9wKAI0CNeqCfnyG7uKSpjJpoVBq-TDAisGBsinmnJx_-iBCe7_E9vkSS8mHR_HSja5_Kvi7tQJUByDT1v3r-l_hHd70oUE</recordid><startdate>201802</startdate><enddate>201802</enddate><creator>Shirasu, Hiromichi</creator><creator>Ono, Akira</creator><creator>Omae, Katsuhiro</creator><creator>Nakashima, Kazuhisa</creator><creator>Omori, Shota</creator><creator>Wakuda, Kazushige</creator><creator>Kenmotsu, Hirotsugu</creator><creator>Naito, Tateaki</creator><creator>Murakami, Haruyasu</creator><creator>Endo, Masahiro</creator><creator>Nakajima, Takashi</creator><creator>Takahashi, Toshiaki</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><general>IOS Press</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>201802</creationdate><title>CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma</title><author>Shirasu, Hiromichi ; Ono, Akira ; Omae, Katsuhiro ; Nakashima, Kazuhisa ; Omori, Shota ; Wakuda, Kazushige ; Kenmotsu, Hirotsugu ; Naito, Tateaki ; Murakami, Haruyasu ; Endo, Masahiro ; Nakajima, Takashi ; Takahashi, Toshiaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3880-a15e86f7045fe9d4fc0faf7b05903cc774b8587f5d97213aaba33494f483bcb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenocarcinoma</topic><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma of Lung</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antigens</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Authorship</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer therapies</topic><topic>Carcinoembryonic antigen</topic><topic>Carcinoembryonic Antigen - metabolism</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Disease-Free Survival</topic><topic>Enzymes</topic><topic>Epidermal growth factor</topic><topic>ErbB Receptors - metabolism</topic><topic>Ethics</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Histology</topic><topic>Humans</topic><topic>Immunoassay</topic><topic>Immunotherapy</topic><topic>Keratin-19 - metabolism</topic><topic>Lung cancer</topic><topic>Lung carcinoma</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multivariate analysis</topic><topic>Mutation</topic><topic>Nivolumab</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Pharmaceuticals</topic><topic>Research funding</topic><topic>Retrospective Studies</topic><topic>Smoking</topic><topic>Squamous cell carcinoma</topic><topic>Statistical analysis</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shirasu, Hiromichi</creatorcontrib><creatorcontrib>Ono, Akira</creatorcontrib><creatorcontrib>Omae, Katsuhiro</creatorcontrib><creatorcontrib>Nakashima, Kazuhisa</creatorcontrib><creatorcontrib>Omori, Shota</creatorcontrib><creatorcontrib>Wakuda, Kazushige</creatorcontrib><creatorcontrib>Kenmotsu, Hirotsugu</creatorcontrib><creatorcontrib>Naito, Tateaki</creatorcontrib><creatorcontrib>Murakami, Haruyasu</creatorcontrib><creatorcontrib>Endo, Masahiro</creatorcontrib><creatorcontrib>Nakajima, Takashi</creatorcontrib><creatorcontrib>Takahashi, Toshiaki</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shirasu, Hiromichi</au><au>Ono, Akira</au><au>Omae, Katsuhiro</au><au>Nakashima, Kazuhisa</au><au>Omori, Shota</au><au>Wakuda, Kazushige</au><au>Kenmotsu, Hirotsugu</au><au>Naito, Tateaki</au><au>Murakami, Haruyasu</au><au>Endo, Masahiro</au><au>Nakajima, Takashi</au><au>Takahashi, Toshiaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma</atitle><jtitle>Tumor biology</jtitle><addtitle>Tumour Biol</addtitle><date>2018-02</date><risdate>2018</risdate><volume>40</volume><issue>2</issue><spage>1010428318760420</spage><epage>1010428318760420</epage><pages>1010428318760420-1010428318760420</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>CYFRA 21-1 is a prognostic marker for non–small cell lung cancer. The serum CYFRA 21-1 level is also known as an adjunct for the diagnosis of lung squamous cell carcinoma. This study aimed to examine whether CYFRA 21-1 has predictive implications for nivolumab therapy in patients with advanced lung adenocarcinoma. Of the 79 patients who were treated with nivolumab therapy at the Shizuoka Cancer Center between December 2015 and September 2016, we retrospectively reviewed the data of 50 patients. The patient characteristics were as follows: age &lt;70/≥70 years: 43 (86%)/7; male/female: 31 (62.0%)/19; Eastern Cooperative Oncology Group performance status 0–1/2: 43 (86%)/7; smoking status: no/yes: 18 (36%)/32; epidermal growth factor receptor mutation status negative/positive: 36 (72%)/14; CYFRA 21-1 ≥2.2/&lt;2.2 ng/mL: 28 (56%)/22; carcinoembryonic antigen ≥5/&lt;5 ng/mL: 29 (58%)/21; and number of prior regimens 2–3/≥4: 16 (32%)/34. With a median follow-up of 263.5 (range, 64–352) days, the median progression-free survival was 70 days. The clinical variables investigated using univariate analysis were as follows: age (p = 0.423), carcinoembryonic antigen (p = 0.888), epidermal growth factor receptor mutation status (p = 0.105), performance status (p = 0.968), sex (p = 0.210), number of prior regimens (p = 0.146), CYFRA 21-1 (p = 0.026), and smoking status (p = 0.041). A multivariate analysis identified a serum CYFRA 21-1 level ≥2.2 ng/mL as an independent predictor of a favorable outcome (hazard ratio, 0.44; 95% confidence interval, 0.23–0.85; p = 0.015; median progression-free survival, 155 vs 51.5 days). In conclusion, CYFRA 21-1 might be an independent predictor of outcome for patients with advanced lung adenocarcinoma treated with nivolumab.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>29463190</pmid><doi>10.1177/1010428318760420</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1010-4283
ispartof Tumor biology, 2018-02, Vol.40 (2), p.1010428318760420-1010428318760420
issn 1010-4283
1423-0380
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_1a88b2cad8c4438abaed8a8e42f13033
source Publicly Available Content Database
subjects Adenocarcinoma
Adenocarcinoma - drug therapy
Adenocarcinoma - metabolism
Adenocarcinoma of Lung
Adult
Aged
Antibodies, Monoclonal - therapeutic use
Antigens
Antigens, Neoplasm - metabolism
Authorship
Biomarkers, Tumor - metabolism
Cancer therapies
Carcinoembryonic antigen
Carcinoembryonic Antigen - metabolism
Chemotherapy
Clinical medicine
Disease-Free Survival
Enzymes
Epidermal growth factor
ErbB Receptors - metabolism
Ethics
Female
Follow-Up Studies
Histology
Humans
Immunoassay
Immunotherapy
Keratin-19 - metabolism
Lung cancer
Lung carcinoma
Lung Neoplasms - drug therapy
Lung Neoplasms - metabolism
Male
Middle Aged
Monoclonal antibodies
Multivariate analysis
Mutation
Nivolumab
Non-small cell lung carcinoma
Patients
Pharmaceuticals
Research funding
Retrospective Studies
Smoking
Squamous cell carcinoma
Statistical analysis
Targeted cancer therapy
Tumors
title CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A47%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CYFRA%2021-1%20predicts%20the%20efficacy%20of%20nivolumab%20in%20patients%20with%20advanced%20lung%20adenocarcinoma&rft.jtitle=Tumor%20biology&rft.au=Shirasu,%20Hiromichi&rft.date=2018-02&rft.volume=40&rft.issue=2&rft.spage=1010428318760420&rft.epage=1010428318760420&rft.pages=1010428318760420-1010428318760420&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1177/1010428318760420&rft_dat=%3Cproquest_doaj_%3E2007121717%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3880-a15e86f7045fe9d4fc0faf7b05903cc774b8587f5d97213aaba33494f483bcb23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2013730590&rft_id=info:pmid/29463190&rft_sage_id=10.1177_1010428318760420&rfr_iscdi=true